All In Biotech

Drug Trial Radar · NCT04588129

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

An Open Label Positron Emission Tomography (PET) Study to Evaluate Dopamine Receptor Occupancy of LB-102 Administered Orally to Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jan 5, 2021

Primary completion

Sep 17, 2021

Study completion Nov 15, 2021

Sponsor

Lead sponsor
LB Pharmaceuticals Inc.Industry
Sponsor type
Industry
Collaborators
Washington University School of Medicine
First posted
Oct 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.

Conditions

  • Schizophrenia

Interventions

  • LB-102Drug

    (N-Methyl amisulpride)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Brain Receptor Occupancy as Measured by Positron Emission TomographyTime frame: 2.5 hours post LB-102 dose
  2. Brain Receptor Occupancy as Measured by Positron Emission TomographyTime frame: 7.5 hours post LB-102 dose
  3. Brain Receptor Occupancy as Measured by Positron Emission TomographyTime frame: 23.5 hours post LB-102 dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Washington University School of Medicine

    St Louis, Missouri

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.